Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Equities

1349

CNE1000000W4

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
2.15 HKD +0.94% Intraday chart for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. -5.70% -15.69%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023, Payable on August 26, 2024 CI
Fudan-Zhangjiang Bio's 2023 Profit Falls MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan MT
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products MT
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China MT
Chinese Regulator Accepts Fudan-Zhangjiang Bio-Pharmaceutical's Application for Bladder Cancer Visualization Drug Trial MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Application CI
Chinese Regulator NMPA Grants Acceptance Notice for Shanghai Fudan-Zhangjiang's Investigational Drug MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Receives the Acceptance Notice for the Investigational New Drug CI
Fudan-Zhangjiang Bio-Pharmaceutical's Cancer Drug Passes Chinese Regulator’s Consistency Evaluation MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Notification of Approval for Supplementary Drug Application CI
Fudan-Zhangjiang's Profit Drops 70.5% in Q3 MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Fudan-Zhangjiang Bio Gets Nod for Cancer Drug Trial MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Receives Acceptance Notice Issued by the National Medical Products Administration of the PRC CI
Fudan-Zhangjiang Bio Puchases Structured Deposit Products MT
Fudan-Zhangjiang Bio Swings to Profit in H1 MT
Fudan-Zhangjiang Bio Enrolls First Patient in FZ-AD004 Clinical Trial MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Announces First Patient Enrolled in Phase I Clinical Trial of FZ-AD004 Antibody Drug Conjugate for the Treatment of Advanced Solid Tumors CI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Fudan-Zhangjiang Bio to Swing to H1 Profit MT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2023 CI
Fudan-Zhangjiang Bio Subscribes for 356 Million Yuan of Ping An Bank’s Structured Deposit Products MT
Certain A Shares of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 19-JUN-2023. CI
Chart Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
More charts
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. - Hong Kong S.E.
  4. News Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
  5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's Anti-Cancer Injectable Passes China's Consistency Evaluation